Ultragenyx (RARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ultragenyx (RARE) Stock Forecast
Analysts expect Ultragenyx (RARE) to earn -$3.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $758.50M. Of 21 analysts, 10 rate the stock Buy or Strong Buy, 11 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 21 ratings average 2.43, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 48% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 9.5% |
| Buy | 8 | 38.1% |
| Hold | 11 | 52.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 21
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 29.1%.
- Fiscal year ending Dec 31, 2026
- -$3.05
- EPS consensus, revenue $758.50M
- Fiscal year ending Dec 31, 2027
- $1.43
- EPS consensus, revenue $978.93M
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.05 | -$4.92 to -$1.07 | 6 | $758.50M | $727.10M to $903.13M | 19 |
| Dec 31, 2027 | $1.43 | -$0.39 to $6.38 | 6 | $978.93M | $842.60M to $1.67B | 19 |
Quarterly Estimates
The EPS consensus rises from -$0.51 for the quarter ending Dec 31, 2026 to -$0.04 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.51 | -$1.18 to $3.11 | 22 | $228.28M | $187.18M to $249.66M | 20 |
| Mar 31, 2027 | -$0.04 | -$0.45 to $0.63 | 3 | $198.70M | $159.00M to $312.10M | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.05 | -$4.08 | -$3.87 | -$3.87 | -$3.95 | N/A |
| Fiscal year ending Dec 31, 2027 | $1.43 | $0.23 | $0.68 | $0.20 | $3.19 | -55.1% |
| Quarter ending Mar 31, 2027 | -$0.04 | -$0.44 | -$0.44 | -$0.47 | $0.27 | N/A |
Frequently Asked Questions About RARE
What is the RARE stock forecast?
Consensus analyst estimates put Ultragenyx's EPS at -$3.05 for the fiscal year ending Dec 31, 2026, on revenue of $758.50M. The consensus rating from 21 analysts is Buy.
How do analysts rate RARE stock?
Of 21 analysts covering Ultragenyx, 2 rate it Strong Buy, 8 Buy, 11 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RARE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.05, with estimates from -$4.92 to -$1.07 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.43, with estimates from -$0.39 to $6.38 from 6 analysts.
What revenue do analysts expect from Ultragenyx next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $758.50M, with estimates from $727.10M to $903.13M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $978.93M, with estimates from $842.60M to $1.67B.
How many analysts cover RARE?
21 analysts rate Ultragenyx stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RARE pages: Overview, Earnings, Forecast, Financials, Competitors